Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer
Equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) was demonstrated in a phase 3 study of patients with metastatic or recurrent non-squamous NSCLC. Long-term findings in 689 patients confirmed equivalent efficacy of CT-P16 and EU-bevacizumab; objective response rates were 45.6 % and 46.1 %, respectively. Response duration, time to progression, progression-free survival, and overall survival were also similar.
Authors
- Alona Oleksiienko
- Zoran Andrić (ORCID: https://orcid.org/0000-0002-1495-2729)
- Eric Baek (ORCID: https://orcid.org/0000-0002-7286-7215)
- Hana Ju (ORCID: https://orcid.org/0000-0002-9504-9995)
- Fedor Moiseenko (ORCID: https://orcid.org/0000-0003-2544-9042)
- Eduardo Yañez Ruiz (ORCID: https://orcid.org/0009-0007-0045-233X)
- Soonbum Kwon (ORCID: https://orcid.org/0000-0002-0517-8647)
- Tamta Makharadze (ORCID: https://orcid.org/0000-0001-6432-1872)
- SinHye Kim
- Claire F. Verschraegen (ORCID: https://orcid.org/0000-0001-6544-3089)
- TaeHong Park (ORCID: https://orcid.org/0000-0003-1922-2810)
- Eun Kyung Lee (ORCID: https://orcid.org/0000-0003-0098-0873)
- HyunAh Kim
- Keumyoung Ahn
- SungHyun Kim (ORCID: https://orcid.org/0000-0002-5068-0644)
- I‐Fen Chang
Institutions
- Universidad de La Frontera (CL)
- Tata Main Hospital (IN)
- National Library of Russia (RU)
- University Hospital Medical Center Bezanijska kosa (RS)
- Celltrion (South Korea) (KR)
- Children's Specialized Hospital (US)
- The Ohio State University (US)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100970
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Celltrion